- Home
- NXPL vs GRML Comparison
NXPL vs GRML Comparison
Compare NXPL & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXPL | GRML |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 29.2M |
| IPO Year | 2011 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NXPL | GRML |
|---|---|---|
| Price | $8.20 | $4.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 3.0M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,869,558.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $0.34 | $0.16 |
| 52 Week High | $9.94 | $18.21 |
Technical Indicators
Market Signals| Indicator | NXPL | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 40.63 |
| Support Level | $5.53 | $0.28 |
| Resistance Level | $8.37 | $7.53 |
| Average True Range (ATR) | 0.79 | 0.61 |
| MACD | -0.11 | -0.24 |
| Stochastic Oscillator | 8.74 | 4.09 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.